Renaissance Capital logo

Freeline Therapeutics Priced, Nasdaq: FRLN

Phase 1/2 biotech developing gene therapies for hemophilia and rare diseases.

Industry: Health Care

Latest Trade: $0.90 +0.03 (+3.0%)

First Day Return: 0.0%

Return from IPO: -95.2%

Industry: Health Care

We are a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We aim to deliver one-time gene therapy treatments that provide functional cures through permanently sustained physiological protein levels, leveraging the high expression enabled by our proprietary gene therapy platform. Our initial focus is on developing treatments for monogenic diseases with high unmet need. We are a fully-integrated biotechnology company with internal expertise and capability across the value chain in gene therapy, including expression platform, research, manufacturing, clinical development and commercialization. Our pipeline includes two programs in the clinic and two late-stage preclinical product candidates, as well as research programs targeting novel applications for systemic gene therapy, for which we have, through owned and in-licensed intellectual property rights, development and worldwide commercial rights.
more less
IPO News for Freeline Therapeutics
more
IPO Data
IPO File Date 07/17/2020
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 8.8
Deal Size ($mm) $159
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 08/06/2020
Offer Price $18.00
Price Range $16.00 - $18.00
Offer Shares (mm) 8.8
Deal Size ($mm) $159
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Stevenage, United Kingdom
Founded 2015
Employees 208
Website www.freeline.life